C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes

ACS Nano
Regina TavanoEmanuele Papini

Abstract

Poly(2-methyl-2-oxazoline) (PMOXA) is an alternative promising polymer to poly(ethylene glycol) (PEG) for design and engineering of macrophage-evading nanoparticles (NPs). Although PMOXA-engineered NPs have shown comparable pharmacokinetics and in vivo performance to PEGylated stealth NPs in the murine model, its interaction with elements of the human innate immune system has not been studied. From a translational angle, we studied the interaction of fully characterized PMOXA-coated vinyltriethoxysilane-derived organically modified silica NPs (PMOXA-coated NPs) of approximately 100 nm in diameter with human complement system, blood leukocytes, and macrophages and compared their performance with PEGylated and uncoated NP counterparts. Through detailed immunological and proteomic profiling, we show that PMOXA-coated NPs extensively trigger complement activation in human sera exclusively through the classical pathway. Complement activation is initiated by the sensing molecule C1q, where C1q binds with high affinity ( Kd = 11 ± 1 nM) to NP surfaces independent of immunoglobulin binding. C1q-mediated complement activation accelerates PMOXA opsonization with the third complement protein (C3) through the amplification loop of the alte...Continue Reading

References

Sep 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·A Gabizon, D Papahadjopoulos
Feb 1, 1996·Journal of Pharmaceutical Sciences·S ZalipskyT M Allen
Jan 1, 1997·Methods in Molecular Biology·E R Stanley
Mar 21, 2001·Molecular Immunology·S V PetersenJ C Jensenius
May 13, 2003·Clinical Pharmacokinetics·Alberto GabizonYechezkel Barenholz
Nov 6, 2007·Biomaterials·Yusuke ArimaHiroo Iwata
Jan 9, 2008·Langmuir : the ACS Journal of Surfaces and Colloids·Rupert KonradiMarcus Textor
Feb 6, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Helena PaïdassiPhilippe Frachet
Nov 17, 2009·Journal of Immunological Methods·P J Lachmann
Mar 30, 2010·Biomaterials·Robert LuxenhoferAlexander V Kabanov
Jan 25, 2011·Journal of Proteome Research·Jürgen CoxMatthias Mann
Apr 2, 2011·Bioconjugate Chemistry·Tacey X ViegasFrancesco M Veronese
May 20, 2011·Nature·Björn SchwanhäusserMatthias Selbach
Nov 1, 2011·Annual Review of Pharmacology and Toxicology·S M MoghimiT L Andresen
Dec 14, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Yanling MaYihui Deng
Apr 12, 2012·Molecular & Cellular Proteomics : MCP·James C WrightJyoti S Choudhary
May 23, 2012·Macromolecular Bioscience·Ning ZhangRainer Jordan
Jun 23, 2012·Journal of Innate Immunity·S M MoghimiA C Hunter
Aug 2, 2012·International Journal of Pharmaceutics·Takuya SuzukiHiroshi Kikuchi
Aug 11, 2012·The Journal of Biological Chemistry·Myriam MartinAnna M Blom
Aug 14, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Justin T SchwartzLee-Ann H Allen
Sep 22, 2012·Macromolecular Rapid Communications·Rupert KonradiMarcus Textor
Oct 5, 2012·Macromolecular Rapid Communications·Ondrej SedlacekMartin Hruby
Feb 26, 2013·Nanomedicine : Nanotechnology, Biology, and Medicine·Alina J AndersenSeyed Moein Moghimi
Apr 9, 2013·Archivum Immunologiae Et Therapiae Experimentalis·Misao MatsushitaTeizo Fujita
Aug 27, 2013·Journal of Materials Science. Materials in Medicine·Victor R de la Rosa
Aug 26, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·László DézsiJános Szebeni
Sep 13, 2014·Journal of the American Chemical Society·Emma M Pelegri-O'DayHeather D Maynard
Apr 8, 2015·Macromolecular Bioscience·Zhijian HeAlexander V Kabanov
Jun 18, 2015·Frontiers in Immunology·Nicolas S MerleLubka T Roumenina
Jul 26, 2015·Langmuir : the ACS Journal of Surfaces and Colloids·Olga KoshkinaAnnabelle Bertin
Jul 28, 2015·Nanoscale·Edward D H MansfieldVitaliy V Khutoryanskiy

❮ Previous
Next ❯

Citations

Feb 2, 2019·Expert Review of Vaccines·Hannah G KellyAdam K Wheatley
Apr 4, 2019·The Journal of Pharmacology and Experimental Therapeutics·S Moein MoghimiA Christy Hunter
Feb 14, 2019·Analytical and Bioanalytical Chemistry·Anna Laura CapriottiSusy Piovesana
Feb 14, 2020·Nanomaterials·Lucía Morillas-BecerrilMarta Trevisan
Sep 27, 2018·Nanomaterials·Francesca Gatto, Giuseppe Bardi
Jun 27, 2019·Materials·Roberta CaglianiGiuseppe Bardi
Feb 19, 2019·Frontiers in Immunology·Bengt Fadeel
Oct 14, 2018·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Miaoyi WangPu Chun Ke
Feb 1, 2020·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Luca DigiacomoGiulio Caracciolo
Oct 13, 2020·Nanotechnology·Paolo DecuzziTwan Lammers
May 12, 2020·Advanced Drug Delivery Reviews·S Moein MoghimiZ Shadi Farhangrazi
Feb 6, 2021·Pharmaceutics·Basmah N AldosariAlanood S Almurshedi
Mar 18, 2021·Biomaterials Science·Lucca TrachselEdmondo M Benetti
Nov 7, 2020·Frontiers in Immunology·Emanuele PapiniFabrizio Mancin
Apr 9, 2021·Advanced Drug Delivery Reviews·Shubham A SalunkheAnupama Mittal
Apr 14, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Wei HuangWeiping Min
May 21, 2021·Nanoscale Research Letters·Zhongyang YuKaiwen Hu
Jun 5, 2021·Advanced Drug Delivery Reviews·Yiyuan KangLongquan Shao
Apr 12, 2019·Journal of Controlled Release : Official Journal of the Controlled Release Society·Geoffrey GiffordDmitri Simberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Antibodies: Complement Activation

The complement system can be activated by antigen-associated antibody. In the classical pathway of complement activation, C1q, C4b, and C3b are all able to bind to the Fc portion of IgG or IgM. Find the latest research on antibodies and complement activation here.